AXL vs BABA

The company exhibits weak fundamental health with a Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score to confirm financial distress risk. Despite a recent strong price run-up (+44.8% 1Y), profitability is thin, growth is negative, and leverage is extremely high (Debt/Equity: 3.81). Valuation metrics are mixed, with a low P/S of 0.17 suggesting potential undervaluation, but elevated P/E of 23.66 and negative earnings growth raise concerns. Analysts concur with a 'hold' rating, aligning with the uncertain outlook.

The Advanced Deterministic Scorecard reveals a mixed financial profile for Alibaba (BABA), with a weak Piotroski F-Score of 4/9 indicating suboptimal financial health, and no available Altman Z-Score limiting distress risk assessment. While valuation metrics appear favorable relative to peers—especially a Price/Sales of 0.41 and Forward P/E of 19.50—earnings growth is sharply negative (YoY EPS down 71%), and recent quarterly beats have reversed into consistent misses over the last four quarters. Strong insider sentiment and a bullish analyst consensus (strong_buy) contrast with deteriorating profitability and weak technical trends (10/100). The stock trades significantly above the Graham Number ($102.68) and intrinsic value estimate ($51.38), suggesting overvaluation unless growth rebounds materially.